Skip to main content

Patient Advocacy

Patient Advocates Play a Crucial Role in Helping Patients Navigate the Healthcare System
Patient Advocacy
January 2024 Vol 17, No 1
Navigating today’s healthcare system can be challenging for anyone, but for older adults, it can be especially difficult. From scheduling appointments to engaging with clinicians to interpreting health insurance coverage, trying to secure the best medical care can be overwhelming, resulting in poor clinical outcomes, emotional distress, and reduced quality of life. Read More ›
U.S. Patients Rely On Generic Medicines But Increases In Drug Shortages Reflect Challenges To Their Long-Term Sustainability
By Monét Stanford
Patient Advocacy
September 2023 Vol 16, No 5
Generic medicines are the backbone of the US prescription drug market, supplying more than 9 out of every 10 prescriptions. And the production of generic medicines overall has been remarkably stable—even during challenges such as the COVID-19 pandemic. Read More ›
Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions
Value-Based Care, Patient Advocacy
May 2023 Vol 16, No 3
The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills. Read More ›
Patient Advocacy Groups Lend Support to BIOSIM Act
Patient Advocacy, Biosimilars
TOP - October 2021 Vol 14, No 6 | Biosimilars
On July 1, 2021, 28 patient advocacy groups submitted a letter demonstrating their support for H.R. 2815, also known as the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, which aims to increase Medicare reimbursement for health systems that prescribe biosimilars to patients. Read More ›
Stakeholders Advocate for Zero Copay Policy to Lower Biosimilars Costs for Medicare Part B Patients
Patient Advocacy
TOP - October 2021 Vol 14, No 6 | Biosimilars
On August 20, 2021, a group of 16 organizations representing patients, consumers, providers, and taxpayers published an open letter to officials from the Centers for Medicare & Medicaid Services and the Department of Health and Human Services asking them to consider enacting a zero copay policy for Medicare Part B patients, a move the groups said would improve access to biosimilars and save seniors in Medicare as much as $3 billion in out-of-pocket costs. Read More ›